Get the Stockscreener App
3.11
4.01%
-0.13
After Hours:
3.12
0.01
+0.32%
Codexis Inc stock is traded at $3.11, with a volume of 1.45M.
It is down -4.01% in the last 24 hours and up +23.90% over the past month.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$3.24
Open:
$3.23
24h Volume:
1.45M
Relative Volume:
1.76
Market Cap:
$257.65M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-2.8018
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
+10.28%
1M Performance:
+23.90%
6M Performance:
-36.66%
1Y Performance:
-14.79%
1-Day Range:
$3.01
$3.23
1-Week Range:
$2.81
$3.38
52-Week Range:
$1.90
$6.08
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
3.11 | 268.42M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
What makes Codexis Inc. stock price move sharplyVolume Spike Monitors - Newser
Codexis Confronts Trade Policy Challenges: Tariffs and Sanctions Threaten Operations - TipRanks
What analysts say about Codexis Inc. stockRapid growth opportunities - Autocar Professional
Is Codexis Inc. a good long term investmentFree Popular Stock Recommendations - PrintWeekIndia
Why Codexis Inc. stock attracts strong analyst attention3x Return Stock Radar - Newser
How Codexis Inc. stock compares to its top competitorsIs CNFRZ stock undervalued or overvalued nowSignificant capital appreciation - jammulinksnews.com
Codexis Inc. Stock Analysis and ForecastRobust investment performance - Autocar Professional
Major Shareholder Makes Bold Move with Codexis Stock Purchase - TipRanks
Enzymatic Solutions Leader Codexis Reveals Growth Strategy at Jefferies Healthcare Conference - Stock Titan
What drives Codexis Inc. stock priceExceptional gains - Autocar Professional
How Codexis Inc. stock performs during market volatilityFree Market Analysis Group - Newser
Biocatalysis And Biocatalyst Market Set for Strong Growth Outlook: Codexis, Amano Enzyme, Biocatalysts - newstrail.com
Codexis, Inc.'s (NASDAQ:CDXS) P/S Is Still On The Mark Following 27% Share Price Bounce - 富途牛牛
What You Can Learn From Codexis, Inc.'s (NASDAQ:CDXS) P/S - simplywall.st
With 59% ownership, Codexis, Inc. (NASDAQ:CDXS) boasts of strong institutional backing - Yahoo.co
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Perspective Therapeutics (CATX) and Codexis (CDXS) - The Globe and Mail
Synthetic Biology Market Key Players AnalysisBota - openPR.com
Codexis, Inc. (NASDAQ:CDXS) Position Increased by Assenagon Asset Management S.A. - Defense World
Opaleye Management Makes a Bold Move with Codexis Stock Purchase! - TipRanks
Millennium Management LLC Has $171,000 Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Bank of America Corp DE Has $364,000 Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Cantor Fitzgerald Forecasts Codexis FY2026 Earnings - Defense World
Squarepoint Ops LLC Has $253,000 Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):